Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 03 Jan 2019
Price : $35 *
At a glance
- Drugs Anlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 14 Dec 2016 Planned End Date changed from 1 Nov 2016 to 1 Mar 2017.
- 14 Dec 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Mar 2017.
- 25 Nov 2016 Planned End Date changed from 1 Aug 2016 to 1 Nov 2016.